Fig. 4

MYCN-driven IGF2BP1 expression is impaired by BRD inhibitors. a MYCN ChIP-seq profile of the IGF2BP1 promoter region. E-Boxes, putative MYC/N-binding sites, are indicated in dark blue. The IGF2BP1 gene is depicted schematically in orange up to the beginning of the second intron. b Western blot (n = 3) and RT-qPCR (n = 6) analysis of IGF2BP1 expression upon MYCN (siMN) compared to control knockdown (siC) in BE(2)-C. c RT-qPCR (n = 3) analysis of indicated nascent mRNAs upon MYCN compared to control knockdown in BE(2)-C (I1—IGF2BP1). d Scheme of putative MYCN regulation by BRD (TF—transcription factor). e Western blot and RT-qPCR analysis of MYCN and IGF2BP1 expression upon treatment of BE(2)-C with indicated BRD inhibitors (n = 3). f Mivebresib response curve in control (black) and I1-KO (red) BE(2)-C (n = 4). g Relief plot depicting the ZIP synergy for combined treatment of BTYNB and Mivebresib in BE(2)-C (n = 3)